181 related articles for article (PubMed ID: 35481397)
1. African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center.
Martini DJ; Goyal S; Switchenko JM; Lechowicz MJ; Allen PB
Leuk Lymphoma; 2022 Sep; 63(9):2094-2101. PubMed ID: 35481397
[TBL] [Abstract][Full Text] [Related]
2. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
Stevens SR; Baron ED; Masten S; Cooper KD
Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort.
Desai M; Liu S; Parker S
J Am Acad Dermatol; 2015 Feb; 72(2):276-85. PubMed ID: 25458019
[TBL] [Abstract][Full Text] [Related]
4. Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome.
Allen PB; Goyal S; Niyogusaba T; O'Leary C; Ayers A; Tarabadkar ES; Khan MK; Lechowicz MJ
JAMA Dermatol; 2022 Nov; 158(11):1293-1299. PubMed ID: 36069854
[TBL] [Abstract][Full Text] [Related]
5. Racial Disparities in Mycosis Fungoides/Sézary Syndrome-A Single-Center Observational Study of 292 Patients.
Gandham AR; Geller S; Dusza SW; Kupper TS; Myskowski PL
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e174-e180. PubMed ID: 38245472
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center.
Geller S; Lebowitz E; Pulitzer MP; Horwitz SM; Moskowitz AJ; Dusza S; Myskowski PL
J Am Acad Dermatol; 2020 Aug; 83(2):430-439. PubMed ID: 31499157
[TBL] [Abstract][Full Text] [Related]
7. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
8. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.
Miyashiro D; Sanches JA
Int J Dermatol; 2022 Apr; 61(4):442-454. PubMed ID: 34435672
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
11. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center.
Zhang Y; Seminario-Vidal L; Varnadoe C; Lu Y; Dong N; Salamanca C; Whiddon S; Bennett J; Hargis R; Liu H; Montejo M; Hussaini M; Harro C; Messina J; Benson K; Pinilla-Ibarz J; Conejo-Garcia J; Sokol L
Leuk Lymphoma; 2022 Jan; 63(1):109-116. PubMed ID: 34467825
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants.
Edelson RL
J Am Acad Dermatol; 1980 Feb; 2(2):89-106. PubMed ID: 6988470
[TBL] [Abstract][Full Text] [Related]
15. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
16. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
[TBL] [Abstract][Full Text] [Related]
17. Survival prediction model for patients with mycosis fungoides/Sezary syndrome.
Zhu L; Han X; Liu Z; Leng S; Shan N; Lv X; Lu K; Hun S; Wu Y; Liu X
Future Oncol; 2020 Nov; 16(31):2487-2498. PubMed ID: 32746631
[No Abstract] [Full Text] [Related]
18. Mycosis Fungoides and Sézary Syndrome: An Update.
Larocca C; Kupper T
Hematol Oncol Clin North Am; 2019 Feb; 33(1):103-120. PubMed ID: 30497668
[TBL] [Abstract][Full Text] [Related]
19. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
